ORCA Therapeutics Chosen for Spotlight Presentation at EACR-AACR-IACR 2024 Conference

Amsterdam, The Netherlands – February 2024

ORCA Therapeutics BV, a leading biopharmaceutical company specializing in oncolytic immunotherapies, proudly announces its selection for a Spotlight Presentation at the prestigious EACR-AACR-IACR 2024 Conference: “How to Bring Basic Science Discoveries to the Clinic.” The conference is scheduled to take place in Dublin, Ireland, from February 27 to 29, 2024.

The abstract titled “Immunological changes in the tumor microenvironment induced by ORCA-010, an oncolytic adenovirus, in early-stage Prostate cancer: Interim results from a Phase I/IIA clinical trial” has been reviewed by independent experts in the field. ORCA Therapeutics is honored to have its groundbreaking research recognized by the esteemed Scientific Committee, who have selected the abstract for a Poster in the Spotlight presentation.

Dr. Wenliang Dong, CEO of ORCA Therapeutics, expressed his excitement about the acknowledgment, stating, “We are delighted to have our research on ORCA-010 highlighted at such a distinguished event. This recognition underscores our commitment to advancing innovative therapies and the meaningful impact ORCA-010 can have on cancer treatment.”

The Spotlight Presentation provides a unique opportunity for ORCA Therapeutics to share its interim results from the Phase I/IIA clinical trial, demonstrating the extra-ordinary ability of ORCA-010 to activate the tumor micro environment and induce anti-tumor immune responses in prostate cancer. The company eagerly anticipates engaging with fellow researchers, clinicians, and industry leaders to exchange insights and explore collaborative opportunities.

ORCA Therapeutics extends its gratitude to the Scientific Committee for this prestigious recognition and looks forward to contributing to the dialogue on translating basic science discoveries into clinical applications.

For further information and media inquiries, please contact:

Dr. Wenliang Dong, Ph.D. MBA

Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com

Stay tuned for updates from ORCA Therapeutics as it continues to lead the charge in advancing oncolytic immunotherapies for cancer treatment.

About ORCA Therapeutics BV: ORCA Therapeutics BV is a cutting-edge biopharmaceutical company dedicated to developing oncolytic immunotherapies for cancer treatment. With a focus on innovative gene therapies, ORCA Therapeutics is committed to improving patient outcomes and addressing unmet medical needs worldwide. Learn more at www.orca-therapeutics.com